KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBT: 2018-2025

Historic EBT for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' EBT fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • As of Q3 2025, Esperion Therapeutics' EBT stood at -$32.0 million, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year EBT high stood at $58.2 million for Q1 2024, and its period low was -$90.9 million during Q1 2021.
  • Moreover, its 3-year median value for EBT was -$32.0 million (2025), whereas its average is -$27.8 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 192.46% in 2024, then tumbled by 171.30% in 2025.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' EBT stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then fell by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then decreased by 2.90% to -$32.0 million in 2025.
  • Its EBT stands at -$32.0 million for Q3 2025, versus -$13.4 million for Q2 2025 and -$41.5 million for Q1 2025.